Improved DETECT-READY MRSA Panel Launched at ECCMID
10 Apr 2012

MOLECULAR DETECTION INC. launched an improved version of the Detect-Ready® MRSA PANEL at the ECCMID Congress last week. The panel is a qualitative real-time PCR in vitro diagnostic test, CE-marked for the detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive S. aureus).

Molecular Detection Inc. (MDI) is developing a range of Detect-Ready® tests, designed to increase the speed and accuracy of infectious disease diagnosis. The improved MRSA Panel which was launched at this year’s ECCMID (European Congress of Clinical Microbiology and Infectious Diseases), has been enhanced by increasing the number of MRSA strains that it can detect. The new kit also shortens the sample preparation process and minimizes the required ‘hands-on’ time.

The Detect-Ready® MRSA Panel is a qualitative real-time PCR test using pre-mixed reagents which require only the addition of DNA from the patient sample to run the panel. Results are provided in less than 3 hours. Samples for testing are simple to obtain using nasal swabs, alone or in combination with perineal swabs, that can be delivered to the laboratory without the need for transport medium. Unlike other testing products that require special handling, Detect-Ready kits are off-the-shelf room temperature-stabilized and require no refrigeration.

Detect-Ready kits are compatible with multiple rt-PCR platforms currently found in most clinical laboratories, including the Roche LightCycler®, Qiagen Rotor-Gene® and Cepheid SmartCycler®. The flexibility to leverage existing infrastructure and equipment to run Detect-Ready panels eliminates the need for additional hospital capital investment.

“We are delighted to offer this improved version of the Detect-Ready MRSA Panel to our growing customer base,” commented David Wilson, MDI’s Vice President for Commercial Operations, Europe. The inclusion of additional covered MRSA strains reinforces the superior performance of our existing test, which was recently reconfirmed in an independent comparative study with a market leading competitor. In addition, the simplicity and ease-of-use of Detect-Ready MRSA is further enhanced with our new streamlined protocol for sample prep.”

The Detect-Ready MRSA Panel is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, the Netherlands, Belgium, Luxembourg, Australia and Israel, and is in late-stage development in the US.

Request Info


Company website

Tags: MRSA

Molecular Detection Inc.
profile photo

Sonia Nicholas
Clinical Diagnostics Editor